Simon Kohl

Simon Kohl on Latent Labs and AI Drug Design

Simon Kohl, founder and CEO of Latent Labs, discusses his launch of Latenty, an agent that goes end-to-end from a prompt to antibody design that works in the lab. He recounts his time at DeepMind co-leading the protein design team and working on AlphaFold 2, then explains how de novo drug design compresses antibody discovery timelines from years to weeks or hours. He describes making biology programmable, partnerships with pharma companies, and why he left DeepMind to found a startup.

48:28